A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
A phase 1/2 trial of Petosemtamab, Pembrolizumab, FOLFIRI in colorectal cancer and head and neck squamous cell carcinoma, run by Merus B.V., now recruiting.
Overview
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03526835 by Merus B.V., with 560 participants planned, started 2018-05-02 and due to reach its primary completion in 2028-05. Interventions recorded: MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX. Conditions listed: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta
Shares Petosemtamab, FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Genmab.
- TrialA Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P
Shares Petosemtamab, Genmab, Head and neck squamous cell carcinoma.
- TrialStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialLiGeR-HN1
Shares Petosemtamab, Genmab, Head and neck squamous cell carcinoma, Pembrolizumab.
- TrialStudy of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast
Shares Petosemtamab, Genmab, Colorectal cancer.
- TrialEfficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Shares Genmab, Head and neck squamous cell carcinoma, Pembrolizumab, Colorectal cancer.
- TermLGR5
Shares Petosemtamab, Head and neck squamous cell carcinoma, Colorectal cancer.